HOME >> BIOLOGY >> NEWS
Herb used to treat migraine headaches could be used to develop new anti-inflammatory drugs

Yale researchers have shown for the first time that a component of the medicinal herb feverfew targets a protein called IkappaB Kinase and halts that proteins role in the inflammation process.

"The results pave the way for the development of novel anti-inflammatory drugs for a variety of illnesses and symptoms, such as headache, swelling, redness and inflammation," said Craig Crews, associate professor of molecular, cell and developmental biology, chemistry and pharmacology at Yale.

Feverfew, which is commonly used as an alternative medicine for migraine headaches, and some other anti-inflammatory medicinal herbs, are rich in a group of compounds thought to mediate the anti-inflammatory nature of these plants. The anti-inflammatory component in feverfew is called parthenolide.

Led by Crews, the research team set out to identify the molecular basis of parthenolides anti-inflammatory activity. Through a combination of chemical and biochemical approaches, the team made a derivative of parthenolide, which they used to look for proteins that bind to parthenolide. They found that IkappaB Kinase was one such binding protein, which is responsible for inflammation.

"We showed that the binding disrupted the proteins ability to function, and we also were able to identify the part of the protein to which the compound binds," said Crews, whose study results are published in the August issue of Chemistry and Biology. "Now that we have identified one inhibitor of this protein, that information can be used to develop additional inhibitors. This is important because a single inhibitor may not always make a successful drug due to side effects, so its always useful to have a series of inhibitors."


'"/>

Contact: Karen N. Peart
karen.peart@yale.edu
203-432-1326
Yale University
8-Aug-2001


Page: 1

Related biology news :

1. Leader in cancer treatment and prevention research honored
2. New study shows hope for treating inhalant abuse
3. International study findings link acne-like rash to effectiveness of new targeted cancer treatment
4. New study indicates arsenic could be suitable as first-line treatment in type of leukaemia
5. Wastewater could treat itself, power city
6. New treatment for fibromyalgia
7. The impact of genetic variations on the treatment of early rheumatoid arthritis
8. Genuine stem cells found in skin might treat hair loss, wounds
9. OneWorld Health compiles comprehensive state of infectious diarrhea treatments, potential solutions
10. Scientist who discovered Sly syndrome finds new research path to explore for treating the disease
11. Early clinical treatment can halt progression of Alzheimers disease, UCI researchers find

Post Your Comments:
(Date:5/21/2013)... Mo. Cancers of all types become most deadly ... Once cancer has reached this stage, it becomes very ... tumors that can develop. Now, researchers at the University ... nanoparticles that target lymphoma tumor cells wherever they may ... of oncology in the MU College of Veterinary Medicine, ...
(Date:5/21/2013)... Society (ACS), the world,s largest scientific society, invites ... & Exposition, September 8-12, 2013, in Indianapolis, Ind. ... Center and at area hotels. , With more ... science,s horizons from astronomy to zoology ― ... journalists a rich assortment of spot news and ...
(Date:5/21/2013)... epigenetic modifications, which alter the way genes function ... be detected in the blood of pregnant women ... to foretell depression in the weeks after giving ... become debilitating. , The findings of the small ... in the journal Molecular Psychiatry . , ...
Breaking Biology News(10 mins):MU researchers develop radioactive nanoparticles that target cancer cells 2Genetic predictors of postpartum depression uncovered by Hopkins researchers 2Genetic predictors of postpartum depression uncovered by Hopkins researchers 3
(Date:5/22/2013)... CAMBRIDGE, Mass. , May 22, 2013  Moderna ... revolutionary new treatment modality to enable the in ... John Reynders will join Moderna ... Reynders is a proven leader in ... phases of drug development, from discovery to translation, clinical ...
(Date:5/21/2013)... 2013 Through science fairs, workshops, kits ... lab equipment, 25 organizations will continue their work to ... and photonics in daily life with the aid of ... located in 10 countries, are the first of two ... SPIE, the international society for optics and photonics ...
(Date:5/21/2013)... 2013 Clinverse, Inc. , ... clinical trials, announced today it has formed a ... Clinverse’s ClinPay® FLS eClinical commerce platform aggregates data ... SpendMD ™, Aggregate Spend Solutions’ recently-launched flagship ... and reporting transfer of value at investigator meetings ...
(Date:5/21/2013)... (PRWEB) May 21, 2013 Emerson ... announced that Dr. Charles Signorino, the Company’s Chief Executive ... 1, 2013 after 32 years of service. As part ... Emerson’s current President, has been named as Dr. Signorino’s ... in the pharmaceutical industry, having made a significant contribution ...
Breaking Biology Technology:Industry Leader John Reynders Joins Moderna Therapeutics as Chief Information Officer 2Industry Leader John Reynders Joins Moderna Therapeutics as Chief Information Officer 3Learning About Light: Education Outreach Projects Funded in 10 Countries Through First Round of SPIE Grants 2Learning About Light: Education Outreach Projects Funded in 10 Countries Through First Round of SPIE Grants 3Clinverse, Inc. Announces Strategic Alliance with Aggregate Spend Solutions, LLC 2Clinverse, Inc. Announces Strategic Alliance with Aggregate Spend Solutions, LLC 3Emerson Resources Announces CEO Retirement and Appointment of Successor 2Emerson Resources Announces CEO Retirement and Appointment of Successor 3
Cached News: